Standardization for subgroup analysis in randomized controlled trials
- PMID: 24392983
- PMCID: PMC4313927
- DOI: 10.1080/10543406.2013.856023
Standardization for subgroup analysis in randomized controlled trials
Abstract
Randomized controlled trials (RCTs) emphasize the average or overall effect of a treatment (ATE) on the primary endpoint. Even though the ATE provides the best summary of treatment efficacy, it is of critical importance to know whether the treatment is similarly efficacious in important, predefined subgroups. This is why the RCTs, in addition to the ATE, also present the results of subgroup analysis for preestablished subgroups. Typically, these are marginal subgroup analysis in the sense that treatment effects are estimated in mutually exclusive subgroups defined by only one baseline characteristic at a time (e.g., men versus women, young versus old). Forest plot is a popular graphical approach for displaying the results of subgroup analysis. These plots were originally used in meta-analysis for displaying the treatment effects from independent studies. Treatment effect estimates of different marginal subgroups are, however, not independent. Correlation between the subgrouping variables should be addressed for proper interpretation of forest plots, especially in large effectiveness trials where one of the goals is to address concerns about the generalizability of findings to various populations. Failure to account for the correlation between the subgrouping variables can result in misleading (confounded) interpretations of subgroup effects. Here we present an approach called standardization, a commonly used technique in epidemiology, that allows for valid comparison of subgroup effects depicted in a forest plot. We present simulations results and a subgroup analysis from parallel-group, placebo-controlled randomized trials of antibiotics for acute otitis media.
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.Health Technol Assess. 2001;5(33):1-56. doi: 10.3310/hta5330. Health Technol Assess. 2001. PMID: 11701102 Review.
-
Antibiotics for acute otitis media: a meta-analysis with individual patient data.Lancet. 2006 Oct 21;368(9545):1429-35. doi: 10.1016/S0140-6736(06)69606-2. Lancet. 2006. PMID: 17055944 Review.
-
Antibiotics versus placebo or watchful waiting for acute otitis media: a meta-analysis of randomized controlled trials.J Antimicrob Chemother. 2009 Jul;64(1):16-24. doi: 10.1093/jac/dkp166. Epub 2009 May 19. J Antimicrob Chemother. 2009. PMID: 19454521 Review.
-
Subgroup effects despite homogeneous heterogeneity test results.BMC Med Res Methodol. 2010 May 17;10:43. doi: 10.1186/1471-2288-10-43. BMC Med Res Methodol. 2010. PMID: 20478021 Free PMC article.
Cited by
-
Treatment effect heterogeneity for univariate subgroups in clinical trials: Shrinkage, standardization, or else.Biom J. 2016 Jan;58(1):133-53. doi: 10.1002/bimj.201400102. Epub 2015 Oct 20. Biom J. 2016. PMID: 26485117 Free PMC article.
-
Improving precision medicine using individual patient data from trials.CMAJ. 2017 Feb 6;189(5):E204-E207. doi: 10.1503/cmaj.160267. Epub 2016 Aug 29. CMAJ. 2017. PMID: 27573743 Free PMC article. Review. No abstract available.
-
Bayesian analysis of heterogeneous treatment effects for patient-centered outcomes research.Health Serv Outcomes Res Methodol. 2016;16(4):213-233. doi: 10.1007/s10742-016-0159-3. Epub 2016 Sep 20. Health Serv Outcomes Res Methodol. 2016. PMID: 27881932 Free PMC article.
-
Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research.J Clin Epidemiol. 2018 Aug;100:22-31. doi: 10.1016/j.jclinepi.2018.04.005. Epub 2018 Apr 11. J Clin Epidemiol. 2018. PMID: 29654822 Free PMC article. Review.
-
Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.CMAJ. 2020 Aug 10;192(32):E901-E906. doi: 10.1503/cmaj.200077. CMAJ. 2020. PMID: 32778601 Free PMC article.
References
-
- Food and Drug Administration. Providing clinical evidence of effectiveness of human drug and biological products. Washington, DC: US Department of Health and Human Services; 1998. Guidance for Industry.
-
- Groenwold RHH, Donders ART, van der Heijden GJMG, Hoes AW, Rovers MM. Confounding of subgroup analyses in randomized data. Archives of Internal Medicine. 2009;169:1532–1533. - PubMed
-
- Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550–560. - PubMed
-
- Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, et al. Antibiotics for acute otitis media: A meta-analysis with individual patient data. Lancet. 2006;368:1429–1435. - PubMed
-
- Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003;14:680–686. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials